An increase in serum phenytoin concentration by changes of dosage form: Case reports and its mechanism

Tomoko Yamaguchi, Shino Mukai, Shigeo Uotani, Hisakazu Ohtani, Yasufumi Sawada

Research output: Contribution to journalArticle

Abstract

Phenytoin (PHT) exhibits nonlinear pharmacokinetics in the therapeutic range. Therefore a slight increase in dose may lead to considerable elevation of the serum PHT level. Although its bioavailability is dependent on the formulation, bioequivalence is considered to be preserved between the three major formulations, of tablet, 97% fine granules, and 10% powder. However, we experienced many cases of increases serum PHT concentration after changes in formulation from 97% fine granules to 97/4% hospital-made fine granules, and from the latter to 10% powder. Retrospective analysis revealed that these alterations were accompanied by 55% and 16% increases in the serum concentration-to-dose ratio of PHT, respectively. We investigated the factors of this increase by analyzing the weight of remaining powder in a package and the PHT content of each formulation. Each package of PHT formulation prepared with 97% fine granules and 10% powder was unsealed, and the contents were weighed to calculate the rate of recovery. The rate of ingestion was estimated by correcting the rate of recovery by PHT strength (i. e., 1.0 for 10% powder and 0.97 for fine granules). The rates of recovery and ingestion for 10% powder were 13% and 16% higher than those for 97% fine granules, respectively (p<0.01). In conclusion, Changing the PHT formulation from 97% fine granules to 10% powder may lead to a considerable increase in the serum PHT concentration and possibly induce PHT toxicity.

Original languageEnglish
Pages (from-to)331-338
Number of pages8
JournalYakugaku Zasshi
Volume122
Issue number5
DOIs
Publication statusPublished - 2002 May
Externally publishedYes

Fingerprint

Dosage Forms
Phenytoin
Powders
Serum
Eating
Therapeutic Equivalency
Biological Availability
Tablets
Pharmacokinetics
Weights and Measures

Keywords

  • Dosage form
  • Phenytoin
  • Serum concentration

ASJC Scopus subject areas

  • Molecular Medicine

Cite this

An increase in serum phenytoin concentration by changes of dosage form : Case reports and its mechanism. / Yamaguchi, Tomoko; Mukai, Shino; Uotani, Shigeo; Ohtani, Hisakazu; Sawada, Yasufumi.

In: Yakugaku Zasshi, Vol. 122, No. 5, 05.2002, p. 331-338.

Research output: Contribution to journalArticle

Yamaguchi, Tomoko ; Mukai, Shino ; Uotani, Shigeo ; Ohtani, Hisakazu ; Sawada, Yasufumi. / An increase in serum phenytoin concentration by changes of dosage form : Case reports and its mechanism. In: Yakugaku Zasshi. 2002 ; Vol. 122, No. 5. pp. 331-338.
@article{084d26307ae940f8a63ed17f6ea92e3d,
title = "An increase in serum phenytoin concentration by changes of dosage form: Case reports and its mechanism",
abstract = "Phenytoin (PHT) exhibits nonlinear pharmacokinetics in the therapeutic range. Therefore a slight increase in dose may lead to considerable elevation of the serum PHT level. Although its bioavailability is dependent on the formulation, bioequivalence is considered to be preserved between the three major formulations, of tablet, 97{\%} fine granules, and 10{\%} powder. However, we experienced many cases of increases serum PHT concentration after changes in formulation from 97{\%} fine granules to 97/4{\%} hospital-made fine granules, and from the latter to 10{\%} powder. Retrospective analysis revealed that these alterations were accompanied by 55{\%} and 16{\%} increases in the serum concentration-to-dose ratio of PHT, respectively. We investigated the factors of this increase by analyzing the weight of remaining powder in a package and the PHT content of each formulation. Each package of PHT formulation prepared with 97{\%} fine granules and 10{\%} powder was unsealed, and the contents were weighed to calculate the rate of recovery. The rate of ingestion was estimated by correcting the rate of recovery by PHT strength (i. e., 1.0 for 10{\%} powder and 0.97 for fine granules). The rates of recovery and ingestion for 10{\%} powder were 13{\%} and 16{\%} higher than those for 97{\%} fine granules, respectively (p<0.01). In conclusion, Changing the PHT formulation from 97{\%} fine granules to 10{\%} powder may lead to a considerable increase in the serum PHT concentration and possibly induce PHT toxicity.",
keywords = "Dosage form, Phenytoin, Serum concentration",
author = "Tomoko Yamaguchi and Shino Mukai and Shigeo Uotani and Hisakazu Ohtani and Yasufumi Sawada",
year = "2002",
month = "5",
doi = "10.1248/yakushi.122.331",
language = "English",
volume = "122",
pages = "331--338",
journal = "Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan",
issn = "0031-6903",
publisher = "Pharmaceutical Society of Japan",
number = "5",

}

TY - JOUR

T1 - An increase in serum phenytoin concentration by changes of dosage form

T2 - Case reports and its mechanism

AU - Yamaguchi, Tomoko

AU - Mukai, Shino

AU - Uotani, Shigeo

AU - Ohtani, Hisakazu

AU - Sawada, Yasufumi

PY - 2002/5

Y1 - 2002/5

N2 - Phenytoin (PHT) exhibits nonlinear pharmacokinetics in the therapeutic range. Therefore a slight increase in dose may lead to considerable elevation of the serum PHT level. Although its bioavailability is dependent on the formulation, bioequivalence is considered to be preserved between the three major formulations, of tablet, 97% fine granules, and 10% powder. However, we experienced many cases of increases serum PHT concentration after changes in formulation from 97% fine granules to 97/4% hospital-made fine granules, and from the latter to 10% powder. Retrospective analysis revealed that these alterations were accompanied by 55% and 16% increases in the serum concentration-to-dose ratio of PHT, respectively. We investigated the factors of this increase by analyzing the weight of remaining powder in a package and the PHT content of each formulation. Each package of PHT formulation prepared with 97% fine granules and 10% powder was unsealed, and the contents were weighed to calculate the rate of recovery. The rate of ingestion was estimated by correcting the rate of recovery by PHT strength (i. e., 1.0 for 10% powder and 0.97 for fine granules). The rates of recovery and ingestion for 10% powder were 13% and 16% higher than those for 97% fine granules, respectively (p<0.01). In conclusion, Changing the PHT formulation from 97% fine granules to 10% powder may lead to a considerable increase in the serum PHT concentration and possibly induce PHT toxicity.

AB - Phenytoin (PHT) exhibits nonlinear pharmacokinetics in the therapeutic range. Therefore a slight increase in dose may lead to considerable elevation of the serum PHT level. Although its bioavailability is dependent on the formulation, bioequivalence is considered to be preserved between the three major formulations, of tablet, 97% fine granules, and 10% powder. However, we experienced many cases of increases serum PHT concentration after changes in formulation from 97% fine granules to 97/4% hospital-made fine granules, and from the latter to 10% powder. Retrospective analysis revealed that these alterations were accompanied by 55% and 16% increases in the serum concentration-to-dose ratio of PHT, respectively. We investigated the factors of this increase by analyzing the weight of remaining powder in a package and the PHT content of each formulation. Each package of PHT formulation prepared with 97% fine granules and 10% powder was unsealed, and the contents were weighed to calculate the rate of recovery. The rate of ingestion was estimated by correcting the rate of recovery by PHT strength (i. e., 1.0 for 10% powder and 0.97 for fine granules). The rates of recovery and ingestion for 10% powder were 13% and 16% higher than those for 97% fine granules, respectively (p<0.01). In conclusion, Changing the PHT formulation from 97% fine granules to 10% powder may lead to a considerable increase in the serum PHT concentration and possibly induce PHT toxicity.

KW - Dosage form

KW - Phenytoin

KW - Serum concentration

UR - http://www.scopus.com/inward/record.url?scp=0036560566&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036560566&partnerID=8YFLogxK

U2 - 10.1248/yakushi.122.331

DO - 10.1248/yakushi.122.331

M3 - Article

C2 - 12040752

AN - SCOPUS:0036560566

VL - 122

SP - 331

EP - 338

JO - Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan

JF - Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan

SN - 0031-6903

IS - 5

ER -